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INTRODUCTION
Polycystic ovarian syndrome (PCOS) is a fairly common clinical phenomenon among infertile patients. Classically these patients have been characterized by presenting with oligoamenorrhea and hyperandrogenism, as well as the usual associated infertility. From the physiopathological point of view, the syndrome is characterized by chronically high levels of luteinizing hormone (LH) and androgens as welt as a peripheral resistance to insulin, which these patients compensate through their high levels of plasma insulin.
The endocrine anomalies presented by these patients make it difficult to obtain an adequate response to the usual ovarian stimulation protocols used in assisted reproduction techniques (ART). It seems that the high plasma LH levels have a deleterious effect on follicular maturation and compromise oocyte quality (9, 14) . It is accepted that these patients also have a greater tendency to miscarriage as a result of oocyte aging, which may come about as a consequence of the high levels of plasmatic LH (4). The literature on this topic shows that the majority of studies use different diagnostic criteria to catalog patients as affected by genuine PCOS, depending on whether clinical, ultrasound, or biochemical criteria are used (6) .
'In vitro fertilization is obviously not the first therapeutic option for PCO patients. Nevertheless, it can happen that a patient with these characteristics has failed after application of the usual therapeutic options for the syndrome or simply that she should undergo IVF because of an associated factor such as tubal pathology of male-factor infertility.
KEY POINTS
Knowing the tendency of these patients to show exaggerated responses when they are stimulated for ART, it is important to find answers to the following questions.
(1) Which stimulation protocol is most appropriate to the hormonal profile of PCO patients?
Most studies agree in pointing out the advantages of using a pituitary suppression protocol with GnRH analogues, which help to normalize the patient's endocrine irregularities (14). Among the GnRHa's we would recommend an analogue such as buserelin with a comparatively intense gonadal action which checks the tendency of these patients toward an explosive response (2, 3).
As for gonadotropin preparations, there is some controversy surrounding the advantages of using FSH preparations over the use of HMG. There are studies which use metaanalysis to conclude that there are no advantages in using either gonadotropin (6) and that the overriding influence is the dose. Nevertheless, we suggest the use of highly purified FSH preparations or recombinant FSH, which we believe allows us to be more physiological in our stimulation of these patients." Regarding the addition of growth hormone (GH), studies published to date show no advantages to be derived from its use (7).
(2) Is the oocyte quality of PCO patients adversely affected?
It is common to obtain a large number of oocytes in IVF cycles carried out in PCO patients. Classically it was said that in these hyperresponsive patients the oocytes are of poor quality (16). However, oocyte donation programs were to prove that oocytes from highly responsive patients could give good embryos with an adequate implantation capacity.
(3) Is the implantation capacity of PCO patients compromised?
PCO patients tend to present high estradiol levels, to which has been attributed a negative effect on embryo implantation (13) . There is, however, controversy on this point, since some authors have demonstrated that the high estradiol levels are compensated by progesterone levels which are also higher than normal, without this affecting endometrial quality as is the case in patients affected by ovarian hyperstimulation syndrome (OHSS) and their usually higher implantation rates.
(4) Do PCO patients who become pregnant after IVF have a greater tendency to miscarry?
Although classically it was accepted that patients with chronically high LH levels have a higher risk of miscarriage (10) , the application of GnRH analogues for pituitary suppression allows LH levels to be reduced and normalizes the miscarriage rate in these patients (8) .
(5) Can we perform prophylaxis for OHS in PCO patients?
OHS is one of the complications which may derive from the hyperresponsiveness typical of PCO patients. Several alternatives have been proposed to reduce the risk.
One alternative is to suspend gonadotropin administration temporarily during 1-6 days (drift period), while waiting for plasma estradiol levels to fall before hCG administration (17).
Another possibility is to freeze all the embryos obtained, restart GnRH analogue administration, and postpone the transfer of frozen embryos until later cycles. Following this protocol, Berg and Hamberger (5) showed that acceptable cumulative pregnancy rates were obtained.
Finally, we must not forget the possibility of intravenous administration of 50 g of albumin during follicular aspiration, with the purpose of increasing the intravascular oncotic pressure and providing a larger protein substrate to compensate for the high levels of sex steroids in the circulation. This strategy has been shown to be most useful in the prevention of OHS in patients with high responses (1, 12) .
CONCLUSIONS
We believe that PCO patients can achieve good results in IVF cycles, provided that stimulation protocols appropriate to their hormonal profiles are used.
The dose of gonadotropin used seems to be more important than the. type of gonadotropin. If there is a risk of ovarian hyperstimulation, it is useful to employ one of the strategies recommended to prevent development of genuine OHS, which may endanger the patient's health.
INTRODUCTION
Polycystic ovary syndrome (PCOS) is a very common cause of anovulation (1), accounting for nearly 75% of patients with anovulatory infertility (2) . The prevalence of polycystic ovarian morphology is even higher; it has been estimated that more than 20% of women in the normal population have polycystic ovaries (PCO) (3) . Although the majority of women with PCO are only mildly symptomatic or asymptomatic, the finding of PCO on ultrasound has considerable implications when considering superovulation for IVF. It has been demonstrated that women with PCO who have regular, ovulatory menses and who present with tubal, male-factor, or unexplained infertility, are much more likely to hyperrespond to gonadotropin therapy than those with normal ovarian morphology. The particular problems associated with superovulation in IVF are premature triggering of the LH surge, reduced quality of eggs and embryos, and, most seriously, ovarian hyperstimulation syndrome (OHSS).
